IDH1 and IDH2 Mutations in Colorectal Cancers

2021/02/04 by Jialing Huang, Li-Hui Tseng, Li‐Hui Tseng +15 · 12 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Genetic factors in colorectal cancer #Colorectal Cancer Treatments and Studies #Inflammatory Bowel Disease

paper · doi:10.1093/ajcp/aqab023

Abstract

OBJECTIVES: To elucidate clinicopathologic and molecular characteristics of IDH1 and IDH2 (IDH1/2) mutations in colorectal cancers (CRCs). METHODS: We evaluated IDH1/2 mutations in 1,623 CRCs using a next-generation sequencing assay. RESULTS: IDH1/2 mutations, predominantly IDH1 p.R132C, were detected in 15 (0.9%) CRCs and in 5 (3.0%) of 167 BRAF p.V600E-mutated CRCs. Three IDH1/2-mutated CRCs were associated with inflammatory bowel disease. They were significantly associated with old age, mucinous or signet ring cell adenocarcinoma, and high-grade histomorphology. Concordance of variant allele frequency between IDH1/2 mutants and other trunk drivers in CRCs and presence of IDH1/2 mutation in the adenoma and early adenocarcinoma indicated IDH1/2 mutations could be trunk drivers suitable for targeted therapy. CONCLUSIONS: IDH1/2 mutations in CRCs were uncommon but enriched in BRAF p.V600E-mutated CRCs and perhaps colitis-associated CRCs. Further studies on IDH1/2-mutated CRCs are needed to clarify their clinicopathologic features and implications for targeted therapy.

Cited by

• Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis. [europepmc]
• Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing. [europepmc]
• IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression. [europepmc]
• Genomic landscape and survival analysis of ctDNA "neo- RAS wild-type" patients with originally RAS mutant metastatic colorectal cancer. [europepmc]
• Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency. [europepmc]
• Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. [europepmc]
• Hippo pathway in intestinal diseases: focusing on ferroptosis. [europepmc]
• Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma. [europepmc]
• Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives. [europepmc]
• C. elegans Cytoplasmic Isocitrate Dehydrogenase Neomorphic G98N and R133H Mutants Produce the Oncometabolite 2-Hydroxyglutarate. [europepmc]
• Genomic characterization of colorectal tumors: insights into significantly mutated genes, pathways, and survival outcomes. [europepmc]
• Machine learning framework for mRNA alternative splicing analysis identifies a signature of progression in colorectal adenocarcinoma. [europepmc]

Related

• Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation
• Genetic susceptibility to non-polyposis colorectal cancer
• Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
• Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers
• Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location